These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12403308)

  • 1. Lidocaine elimination in patients with liver cirrhosis.
    Wójcicki J; Kozłowski K; Droździk M; Wójcicki M
    Acta Pol Pharm; 2002; 59(4):321-4. PubMed ID: 12403308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
    Wojcicki J; Kozlowski K; Drozdzik M; Wojcicki M
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):243-7. PubMed ID: 12587953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
    Testa R; Campo N; Caglieris S; Risso D; Alvarez S; Arzani L; Giannini E; Lantieri PB; Celle G
    Hepatogastroenterology; 1998; 45(19):154-9. PubMed ID: 9496506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.
    Fasoli A; Giannini E; Botta F; Romagnoli P; Risso D; Celle G; Testa R
    Hepatogastroenterology; 2000; 47(31):234-8. PubMed ID: 10690614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis.
    Tonsuwannont W; Praisontarangkul OA; Manorot M; Klangwarnwong D
    J Med Assoc Thai; 1996 May; 79(5):309-19. PubMed ID: 8708523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?
    Testa R; Valente U; Risso D; Caglieris S; Giannini E; Fasoli A; Botta F; Dardano G; Lantieri PB; Celle G
    Eur J Gastroenterol Hepatol; 1999 May; 11(5):559-63. PubMed ID: 10755262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
    Huang YS; Lee SD; Deng JF; Wu JC; Lu RH; Lin YF; Wang YJ; Lo KJ
    J Hepatol; 1993 Aug; 19(1):140-7. PubMed ID: 8301034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
    Testa R; Caglieris S; Risso D; Arzani L; Campo N; Alvarez S; Giannini E; Lantieri PB; Celle G
    Am J Gastroenterol; 1997 Dec; 92(12):2268-73. PubMed ID: 9399768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
    Kupcová V; Turecký L; Szántová M; Schmidtová K
    Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoethylglycinexylidide (MEGX) as a liver function test in cirrhosis.
    Bhise SB; Dias RJ
    Indian J Gastroenterol; 2007; 26(4):167-9. PubMed ID: 17986743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.
    Ercolani G; Grazi GL; Callivà R; Pierangeli F; Cescon M; Cavallari A; Mazziotti A
    Surgery; 2000 Apr; 127(4):464-71. PubMed ID: 10776439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.
    Muñoz AE; Miguez C; Rubio M; Bartellini M; Levi D; Podestá A; Niselman V; Terg R
    Dig Dis Sci; 1999 Apr; 44(4):789-95. PubMed ID: 10219840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Schulz M; Schmidt FW; Herrmann H
    Ther Drug Monit; 1990 May; 12(3):219-26. PubMed ID: 2349604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat model of liver cirrhosis and man.
    Kaneko H; Otsuka Y; Katagiri M; Maeda T; Tsuchiya M; Tamura A; Ishii T; Takagi S; Shiba T
    Clin Exp Med; 2001 Mar; 1(1):19-26. PubMed ID: 11467398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function].
    Klinker H; Joeres R; Bomhard M; Keller F; Dorer J; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():52-5. PubMed ID: 7483715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
    Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
    Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
    Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.